Compare SOUN & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOUN | IDYA |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.9B |
| IPO Year | N/A | 2019 |
| Metric | SOUN | IDYA |
|---|---|---|
| Price | $7.92 | $32.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 16 |
| Target Price | $16.83 | ★ $51.21 |
| AVG Volume (30 Days) | ★ 21.7M | 789.8K |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $218,710,000.00 |
| Revenue This Year | $102.14 | N/A |
| Revenue Next Year | $37.14 | $97.58 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3024.43 |
| 52 Week Low | $6.52 | $13.45 |
| 52 Week High | $22.17 | $39.28 |
| Indicator | SOUN | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 37.34 | 48.38 |
| Support Level | $7.04 | $29.47 |
| Resistance Level | $7.85 | $33.03 |
| Average True Range (ATR) | 0.59 | 1.58 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 35.72 | 63.21 |
SoundHound AI Inc is an innovator of conversational intelligence, offering an independent Voice AI platform that enables businesses across industries to deliver high-quality conversational experiences to customers. The company's voice AI delivers speed and accuracy in numerous languages to product creators and service providers across retail, financial services, healthcare, automotive, smart devices, and restaurants via groundbreaking AI-driven products like Smart Answering, Smart Ordering, Dynamic Drive-Thru, and Amelia AI Agents.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.